Skip to main content
. Author manuscript; available in PMC: 2017 Aug 7.
Published in final edited form as: ACS Appl Mater Interfaces. 2017 May 10;9(20):16900–16912. doi: 10.1021/acsami.7b03877

Figure 6.

Figure 6

(A) In vivo imaging of tumor-bearing mice after 0.5, 3, 8, 12, 24, and 48 h of administration with PBS, DiR, and T1k2k-TOS-DiR. The tumor area of the mouse treated with T1k2k-TOS-DiR is indicated by oval. (B) Ex vivo fluorescence imaging of excised organs: tumor, liver, kidney, spleen, heart, and lung after 48 h of treatment.